"We believe preclinical data on ISM3091's potent anti-tumor activity, tolerability, and pharmacokinetics set the compound apart from competing USP1 inhibitors and make it an important addition to Exelixis' growing clinical-stage pipeline," Dana Aftab, PhD, Exelixis executive vice president, Discovery and Translational Research and chief scientific officer, said in a statement.